Nuclear Medicine advanced
Peptide Radioligand Therapy
Targeted radionuclide therapy using radiolabeled peptides for peptide receptor radionuclide therapy in neuroendocrine tumors.
By Encyclopeptide Editorial | 1 min read
radioligand radionuclide PRRT neuroendocrine targeted-therapy
Overview
Peptide receptor radionuclide therapy (PRRT) delivers cytotoxic radiation to tumors expressing somatostatin receptors using radiolabeled somatostatin analogs.
Approved Radioligand Therapies
| Agent | Peptide | Radionuclide | Indication |
|---|---|---|---|
| Lutathera | Octreotate | Lu-177 | GEP-NET |
| Pluvicto | PSMA-617 | Lu-177 | Prostate cancer |
PRRT Mechanism
- Radiolabeled peptide binds somatostatin receptor
- Receptor-mediated internalization
- Intracellular radionuclide delivery
- Beta-particle emission (Lu-177: beta max 498 keV)
- DNA damage and cell death
Clinical Applications
- Gastroenteropancreatic neuroendocrine tumors (GEP-NET)
- Metastatic castration-resistant prostate cancer
- Meningiomas (investigational)
Test Your Knowledge
Reinforce what you learned about Peptide Radioligand Therapy with interactive quizzes on Wikipept.
Take a Quiz on Wikipept